Introduction:

The global clinical development landscape is undergoing a period of recalibration. Rising trial costs, constrained funding environments, and persistent macroeconomic pressures such as inflation are forcing sponsors to rethink how and where they conduct studies. These pressures are not abstract; they translate directly into slower development timelines, delayed decision-making, and increased risk for sponsors. At the same time, the urgency for new therapies has not diminished.

In this evolving landscape, Contract Research Organizations in India and globally play a critical role in enabling efficient clinical development. As sponsors increasingly explore multi-regional clinical trials (MRCTs), selecting the right countries and partnering with the top CROs in India becomes essential for ensuring successful execution, faster recruitment, and regulatory acceptance.

In several indications, particularly those with a clear unmet medical need, multiple sponsors are pursuing development programs simultaneously. While this reflects scientific progress, it also creates a highly competitive clinical trial environment. When multiple trials target the same patient population within the same geographies, enrollment becomes a bottleneck. Competitive recruitment slows down timelines, increases costs, and can even compromise study feasibility.

One of the most practical and effective ways to address this challenge is through strategic expansion into additional geographies, executed not as an afterthought, but as a core component of trial design within multi-regional clinical trials (MRCTs).

Understanding Multi-Regional Clinical Trials (MRCTs)

A multi-regional clinical trial (MRCT) is designed to generate data across multiple regions simultaneously, with the intent of supporting global or near-simultaneous regulatory submissions.

Large, research-driven pharmaceutical companies have long adopted this model to reduce the time lag between approvals in key markets and to ensure faster patient access to innovative therapies. Over time, MRCTs have evolved from being an advantage to becoming an expectation, particularly for products intended for global markets.

Dr Deepa Arora, CEO of CLINEXEL states, “I have noted that for emerging biotech companies and smaller sponsors, the transition to MRCTs is often complex. Many of these organizations lack prior experience in global trial execution and may be hesitant to expand beyond their home countries. Concerns around regulatory complexity, unfamiliar operational environments, and increased cost exposure are common. For companies operating with limited capital, these concerns are valid. Yet, paradoxically, restricting trials to a narrow set of countries often leads to slower recruitment and longer timelines, ultimately increasing overall development costs.”

Global Collaboration Models and the Role of CROs in India

This is where collaborative global models become highly relevant. AICROS was established in Bremen, Germany, in 2013 with the vision of enabling high-quality global clinical trials through a network of local expert clinical research organizations in India and globally. Rather than operating as a centralized CRO, AICROS brings together regionally specialized partners who possess deep knowledge of local regulatory frameworks, strong relationships with investigators, and a clear understanding of cultural and medical practice nuances. All members operate in alignment with ICH GCP, ensuring globally acceptable data quality.

Within this network, CLINEXEL plays a key role in enabling clinical trials in India. As a full-service pharmaceutical CRO in India and a full member of AICROS since 2020, CLINEXEL provides end-to-end clinical trial services, including regulatory strategy, site identification, project management, and vendor coordination. The organization has strong experience navigating the regulatory environment governed by CDSCO and maintains established relationships with key opinion leaders and high-performing clinical sites across therapeutic areas.

Across the AICROS network, more than one hundred clinical trials have been conducted across diverse therapeutic areas, with operational reach spanning over eighty countries. This breadth of coverage provides sponsors with flexibility in designing geographically diverse studies. However, the availability of multiple countries does not imply that more is always better. One of the most common pitfalls in MRCT design is over-expansion.

Why Country Selection is Critical in MRCT Strategy

Selecting countries for a multi-regional clinical trial (MRCT) is not a matter of geographic representation; it is a strategic decision that directly influences study timelines, cost efficiency, and regulatory success.

A poorly selected country mix can result in:

• Slow enrollment
• Inconsistent data
• Challenges in regulatory acceptance

Conversely, a well-balanced selection can:

• Accelerate recruitment
• Enhance data robustness
• Support smoother global submissions

Based on practical experience, a focused strategy involving approximately 6 to 10 countries tends to be more effective than a broad approach involving twenty or more countries. A smaller, well-chosen set allows for better oversight, reduced variability, and more predictable execution.

Key Factors in MRCT Country Selection

A structured and evidence-based approach is essential when selecting countries for a multi-regional clinical trial (MRCT). The objective is to identify geographies that collectively provide a balance of recruitment potential, regulatory relevance, and operational feasibility.

1. Patient Recruitment Potential

Recruitment potential is often the primary driver. Countries with large patient populations, particularly those with unmet medical needs or limited access to advanced therapies, can significantly accelerate enrollment.

However, recruitment projections must be realistic. Overestimation is a common issue, especially when competitive trials are not adequately considered. Close engagement with investigators and sites is critical to understanding actual patient availability.

2. Regulatory Acceptance and Compliance

Regulatory acceptance is equally important. Data generated from selected countries must be acceptable to major regulatory authorities such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).

These agencies expect consistency in treatment effects across regions and may require additional analyses if variability is observed. The framework for achieving this consistency is outlined in ICH E17.

3. Standard of Care Alignment

CLINEXEL CSO, Dr Mukesh states, “Standard of care alignment is another critical consideration. Differences in medical practice, background therapies, and disease management approaches can introduce variability that complicates data interpretation.”

Ensuring alignment in standard of care helps maintain consistency, strengthen pooled data analysis, and improve overall study validity.

4. Operational Feasibility

Operational feasibility underpins all strategic decisions. This includes:

• Quality and experience of investigative sites
• Adherence to GCP standards
• Regulatory and ethics approval timelines
• Infrastructure capabilities (labs, imaging, storage)

Even the most strategically selected country can become a bottleneck if execution is weak.

CLINEXEL approaches feasibility through detailed, physician-led assessments, ensuring protocol requirements are practical within the local context.

India’s Role in Multi-Regional Clinical Trials

India has emerged as an increasingly important geography in global clinical development. With a large and diverse patient population, improving regulatory frameworks, and growing alignment with international standards, the country offers significant advantages for sponsors and CRO companies in India.

The regulatory environment in India, governed by CDSCO, has evolved significantly in recent years, with greater emphasis on transparency, timelines, and patient safety. Experienced clinical trials companies in India such as CLINEXEL are well-equipped to navigate these requirements.

India also offers:

• Strong clinical expertise
• Experienced investigators
• Expanding research infrastructure

When integrated into a well-designed MRCT, India contributes meaningfully to both recruitment and data diversity.

Common Challenges and Misconceptions in MRCT

Despite the advantages of multi-regional clinical trials, several misconceptions persist.

Regulatory Delays Are the Main Problem

In reality, many delays originate from poor country selection and weak feasibility planning rather than regulatory timelines alone.

More Countries Means Better Results

While diversity is important, excessive expansion introduces operational complexity, data variability, and execution challenges.

MRCTs Are Too Expensive for Small Sponsors

While initial investment may be higher, MRCTs often reduce timelines, improve efficiency, and lower long-term development costs.

Conclusion: Country Selection as a Strategic Lever

Selecting countries for a multi-regional clinical trial (MRCT) is one of the most critical decisions in clinical development. It requires a balance of scientific rationale, regulatory strategy, and operational execution.

A well-designed MRCT, supported by thoughtful country selection, can accelerate timelines, improve data quality, and enable global regulatory approvals.

In this context, partnering with the top CROs in India becomes a key strategic advantage. Organizations like CLINEXEL, recognized among the best CRO in India, bring the expertise, regulatory understanding, and operational excellence required to successfully execute global clinical trials.

In today’s competitive and resource-constrained environment, country selection is no longer a tactical decision — it is a strategic lever that can determine the success or failure of a clinical development program.

 

FAQ’s

What is a multi-regional clinical trial (MRCT)?

A multi-regional clinical trial (MRCT) is a clinical study conducted simultaneously across multiple countries or regions. It is designed to generate globally acceptable data and support regulatory submissions in multiple markets at the same time.

Why are MRCTs important in global drug development?

MRCTs help reduce the time gap between regulatory approvals across different countries. They enable faster patient access to innovative therapies and improve the efficiency of clinical development programs.

How should countries be selected for an MRCT?

Countries should be selected based on a balance of factors including patient recruitment potential, regulatory acceptance, standard of care alignment, and operational feasibility. Strategic selection helps improve timelines and data quality.

How many countries should be included in a multi-regional clinical trial?

In most cases, selecting around 6 to 10 well-chosen countries is more effective than including a large number of countries. A focused approach improves execution, reduces variability, and enhances overall study efficiency.

What are the key factors affecting country selection in MRCTs?

Key factors include:

• Patient recruitment potential
• Regulatory requirements and acceptance
• Standard of care differences
• Operational feasibility and site capability
• Competitive trial landscape

What are common challenges in MRCT execution?

Common challenges include:

• Over-expansion into too many countries
• Inaccurate feasibility assessments
• Recruitment competition
• Variability in standard of care
• Operational complexity across regions

Is India a suitable country for MRCTs?

Yes, India is increasingly recognized as an important geography for multi-regional clinical trials due to its large patient population, improving regulatory environment, experienced investigators, and growing clinical research infrastructure.

Are MRCTs more expensive than single-country trials?

While MRCTs may require higher initial investment, they often reduce overall development timelines and improve efficiency, which can lead to lower total development costs in the long run.

What role do CROs play in MRCTs?

Contract Research Organizations (CROs) support MRCTs by providing regulatory expertise, site management, operational execution, and local market knowledge. Experienced CROs help ensure compliance, efficiency, and data quality across regions.

 

Authors:

Dr. Deepa Arora- CEO- CLINEXEL (https://www.linkedin.com/in/deepaarora2019/)

Dr Deepa is a physician with 25+ years of industry experience in leadership positions with pharma in Clinical Development, Medical Research, and Drug Safety departments.

Dr. Deepa led an industry consortium for the implementation of additional risk minimization measures in Europe. Her experience includes the development and execution of clinical development strategy and conducting clinical trials for NCEs, biosimilars, vaccines, complex generics, and repurposed drugs. 

Deepa has experience in interacting with various regulators- USFDA, EMA, MHRA, MEB, Health Canada, WHO, TGA for scientific advice, pre-IND meetings, end of phase meetings to discuss clinical development path, clinical trial designs, and post-marketing commitments, including PMS/ Phase IV studies and paediatric investigation plan (PIP). 

 

Dr. Mukesh Kumar– Chief Scientific Officer- CLINEXEL (https://www.linkedin.com/in/dr-mukesh-kumar-m-d-6223457/)

A Physician (MD) with over 25 years of deep expertise in clinical R&D, Dr Kumar’s career is a testament to innovation and excellence in clinical trials, clinical pharmacology, translational research, biopharmaceutics, and clinical development. His contributions have driven global product registrations across regulatory landscapes, including the USFDA, EMA, India, PMDA, and ROW regions.

Dr. Kumar’s illustrious career includes clinical R&D leadership roles at global pharmaceutical giants (Sanofi and Daiichi Sankyo) and large Indian pharma companies (CIPLA, DRL, and LUPIN), where he supported early and late phase clinical trials of innovative products, including repurposed drugs via 505(b)(2) path, complex generics, and biosimilars. He has played a key role in transforming the R&D business through clinical risk mitigation strategies and high-quality clinical trial executions. With a proven track record of significant contributions in clinical development of over 100 successful product registrations in the U.S. and Europe, he has redefined efficiencies in clinical strategies by implementing cost-effective, innovative clinical trials and pharmacology studies.

As CLINEXEL’s CSO, Dr. Kumar oversees clinical trial operations (Phases I-IV) and clinical program management. His value-added support is available for CLINEXEL-managed clinical trials in optimizing clinical strategies, global clinical development, and driving impactful scientific negotiations for innovative therapies, biosimilars, and complex generics.